双极雄激素疗法治疗去势抵抗性前列腺癌的研究进展  

Progress in bipolar androgen therapy for castration resistant prostate cancer

作　　者：朱梅开 王健 曲思凤[1] 张秋洁[1] 陈守臻[1] 王文富 王硕 郭虎[1] 史本康[1] 朱耀丰[1] Zhu Meikai;Wang Jian;Qu Sifeng;Zhang Qiujie;Chen Shouzhen;Wang Wenfu;Wang Shuo;Guo Hu;Shi Benkang;Zhu Yaofeng(Department of Urology,Qilu Hospital,Shandong University,Jinan 250012,China;'Department of Urology Leling peoples Hospital,Leling 253600,China)

机构地区：[1]山东大学齐鲁医院泌尿外科,济南250012 [2]乐陵市人民医院泌尿外科,乐陵253600

出　　处：《中华泌尿外科杂志》2023年第12期953-956,共4页Chinese Journal of Urology

摘　　要：双极雄激素疗法(BAT)作为一种新型治疗方法可有效降低部分去势抵抗性前列腺癌(CRPC)患者的血清前列腺特异性抗原(PSA)水平、延缓肿瘤进展,提高其生活质量并恢复对药物治疗的敏感性,本文对BAT的产生背景、可能机制、临床研究进展、发展前景等作一综述。Bipolar androgen therapy(BAT),as a new therapy,can effectively reduce the serum prostate specific antigen(PSA)level of a part of patients with castration resistant prostate cancer(CRPC),delay tumor progression,improve their quality of life and restore the sensitivity to drug therapy.This paper will review the background,possible mechanism,clinical research progress and development prospect of BAT.

关 键 词：前列腺肿瘤 癌 双极雄激素疗法 去势抵抗性前列腺癌 药物协同 雄激素受体 

分 类 号：R737.25[医药卫生—肿瘤]